Natalizumab: A new treatment for relapsing remitting multiple sclerosis

@article{Hutchinson2007NatalizumabAN,
  title={Natalizumab: A new treatment for relapsing remitting multiple sclerosis},
  author={Michael Hutchinson},
  journal={Therapeutics and Clinical Risk Management},
  year={2007},
  volume={3},
  pages={259 - 268}
}
Natalizumab, a new disease-modifying therapy for relapsing remitting multiple sclerosis (RRMS), is a humanized monoclonal antibody which binds to alpha(4)beta(1)-integrin. In a Phase 3 trial, 2 years of natalizumab monotherapy reduced the mean annualized relapse rate (ARR) by 68% compared with placebo (p < 0.001) and the risk of sustained disability progression was reduced by 42% in the natalizumab group (hazard ratio [HR] 0.58; 95% confidence interval [CI] 0.43-0.77; p < 0.001). Natalizumab… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 23 extracted citations

Natalizumab for relapsing remitting multiple sclerosis.

The Cochrane database of systematic reviews • 2011
View 3 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 45 references

A controlled trial of natalizumab for relapsing multiple sclerosis.

The New England journal of medicine • 2003
View 17 Excerpts
Highly Influenced

Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis

CM Dalton, KA Miszkiel, GJ Barker
J Neurol, • 2004
View 3 Excerpts
Highly Influenced

Specific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer 1.

Proceedings of the National Academy of Sciences of the United States of America • 2000
View 8 Excerpts
Highly Influenced

Vascular cell adhesion molecule 1 induces T-cell antigen receptor-dependent activation of CD4+T lymphocytes.

Proceedings of the National Academy of Sciences of the United States of America • 1991
View 8 Excerpts
Highly Influenced

Incidence and clinical signifi cance of antibodies during treatment with natalizumab : 2 year results from AFFIRM and SENTINEL

P Calabresi, G Giovannoni, C Confavreux
Neurology • 2007
View 1 Excerpt

Evaluation for progressive multifocal leukoencephalopathy in natalizumab treated patients

TA Yousry, E Major, C Ryschkewitsch
N Engl J Med, • 2006

Natalizumab improves health - related quality of life in patients with relapsing multiple sclerosis

RA Rudick, A Sandrock
Neurology • 2006

Similar Papers

Loading similar papers…